COMPENDIUM ON FUNCTIONAL MEDICINE - Flipbook - Page 374
and management strategies. By identifying and addressing the
unique patterns of immune reactivity in each individual, we open
new possibilities for meaningful intervention in what has long been
considered an inevitable decline [43, 44].
This represents not just a new test, but a fundamentally new
paradigm - one that offers genuine hope through precision
medicine approaches to what has been one of medicine's most
intractable challenges [45, 46].
References
[1] Jack CR Jr, et al. Hypothetical model of dynamic biomarkers of
the Alzheimer's pathological cascade. Lancet Neurol.
2010;9(1):119-128.
[2] Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's
disease at 25 years. EMBO Mol Med. 2016;8(6):595-608.
[3] Vojdani A. Immune reactivity in Alzheimer's disease: diagnostic
and therapeutic considerations. J Alzheimers Dis. 2019;68(1):25-41.
[4] Cyrex Laboratories. Alzheimer's LINX - Alzheimer's-Associated
Immune Reactivity. 2021.
[5] Goedert M, Spillantini MG. A century of Alzheimer's disease.
Science. 2006;314(5800):777-781.
[6] Jack CR Jr, et al. Tracking pathophysiological processes in
Alzheimer's disease: an updated hypothetical model of dynamic
biomarkers. Lancet Neurol. 2013;12(2):207-216.
[7] Vojdani A, et al. Antibodies against food antigens in Alzheimer's
disease. J Alzheimers Dis. 2018;63(3):1423-1438.
[8] Vojdani A, Lambert J. The role of Th17 in neuroimmune
disorders: target for CAM therapy. Part I. Evid Based Complement
Alternat Med. 2011;2011:927294.
374
